A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

NCT00383162 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

173

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine Disorders

Interventions

DRUG: Combination Product (sumatriptan succinate / naproxen sodium)
DRUG: Placebo

Sponsor

GlaxoSmithKline